Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02323906 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02323906 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 12 participants.
The verdict
NCT02323906, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC. The dose escalation phase of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part of the study using the optimal combination dose regimen.
Interventions
- DRUG Sorafenib
- DRUG CC-122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-01-16 |
| Est. Completion | 2016-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02323906
The ClinicalTrials.gov registry entry for NCT02323906 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT02323906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02323906 about?
NCT02323906 is a clinical study titled "Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer". CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC. The dose escalation phase of the study will explore several dose levels of CC-122 in combination w...
What is the current status of trial NCT02323906?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-01-16. Estimated completion is 2016-12-21.
What interventions are being tested in trial NCT02323906?
The interventions under investigation include: Sorafenib (DRUG), CC-122 (DRUG).
Who is sponsoring clinical trial NCT02323906?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.